RxDoctor Payments Data

Saima Lodhi, MD

Internal Medicine · San Diego, CANPI 1215963590

Payments from drug & device makers

$3,910in general payments, 2019–2025

Across 52 payments — averaging $75.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$2K
  • Cue Health Inc.$867
  • Novo Nordisk$465
  • Lilly USA, LLC$459
  • Viiv Healthcare Company$181
  • AbbVie$92
  • plus $97 from 2 others

What the payments were for

  • Consulting fees$1,75045%
  • Food & beverage$1,29333%
  • Gifts$86722%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead1$1,750
Cue Health Inc.1$867
Novo Nordisk27$465
Lilly USA, LLC6$459
Viiv Healthcare Company8$181
AbbVie4$92
Abbott3$58
Amgen2$39

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,910 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$125,608
Medicare patients
275
Services billed
1,907

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide29$38,382
OzempicSemaglutide26$32,579
SynthroidLevothyroxine Sodium56$4,868
Estradiol64$2,931
Rosuvastatin Calcium165$2,900
Esomeprazole Magnesium13$2,403
Levothyroxine Sodium154$2,107
Alendronate Sodium42$1,797
Bupropion XlBupropion Hcl47$1,648
Celecoxib32$1,427
Duloxetine Hcl39$1,298
Omeprazole57$1,238
Atorvastatin Calcium133$1,131
Metoprolol Succinate50$1,026
Albuterol Sulfate HfaAlbuterol Sulfate21$1,012

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$459$38,38229 claims
Novo NordiskOzempic$465$32,57926 claims
AbbVieSynthroid$92$4,86856 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →